Evidence map›Paper›PMID 25002996›Full record

ArticleRare diseases (Austin, Tex.)2013

Xeroderma Pigmentosum-Trichothiodystrophy overlap patient with novel XPD/ERCC2 mutation.

Henrik H Kralund, Lilian Ousager, Nicolaas G Jaspers, Anja Raams, Erling B Pedersen, Else Gade, Anette Bygum

Open access · bronzeAbstract read
In one paragraph

Article in Rare diseases (Austin, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Henrik H KralundDepartment of Dermatology and Allergy Centre; Odense University Hospital; Odense, Denmark.
Lilian OusagerDepartment of Clinical and Medical Genetics; Odense University Hospital; Odense, Denmark.
Nicolaas G JaspersDepartment of Genetics; Erasmus Medical Center; Rotterdam, Netherlands.
Anja RaamsDepartment of Genetics; Erasmus Medical Center; Rotterdam, Netherlands.
Erling B PedersenDepartments of Medical Research and Medicine; University of Aarhus and Holstebro Hospital; Aarhus, Denmark.
Else GadeDepartment of Ophthalmology; Odense University Hospital; Odense, Denmark.
Anette BygumDepartment of Dermatology and Allergy Centre; Odense University Hospital; Odense, Denmark.
Odense University Hospital · DKErasmus MC · NLRegional Hospital Holstebro · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xeroderma Pigmentosum (XP), Trichothiodystrophy (TTD) and Cockayne Syndrome (CS) are rare, recessive disorders caused by mutational defects in the Nucleotide Excision Repair (NER) pathway and/or disruption of basic cellular DNA transcription. To date, a multitude of mutations in the XPD/ERCC2 gene have been described, many of which give rise to NER- and DNA transcription related diseases, which share certain diagnostic features and few overlap patients have been described. Despite increasing understanding of the roles of XPD/ERCC2 in mammalian cells, there is still weak predictability of somatic outcome from many of these mutations. We demonstrate a patient, believed to represent an overlap between XP and TTD/CS. In addition to other organ dysfunctions, the young man presented with Photosensitivity, Ichthyosis, Brittle hair, Impaired physical and mental development, Decreased fertility and Short stature (PIBIDS) suggestive of TTD, but lacking the almost patognomonic "tiger tail" banding of the hair under polarized light. Additionally, he developed basal cell carcinoma aged 28, as well as adult onset kidney failure, features normally not associated with TTD but rather XP/CS. His freckled appearance also suggested XP, but fibroblast cultures only demonstrated x2 UV-sensitivity with expected NER and TFIIH-activity decrease. Genetic sequencing of the XPD/ERCC2 gene established the patient as heterozygote compound with a novel, N-terminal Y18H mutation and a known C-terminal (TTD) mutation, A725P. The possible interplay between gene products and the patient phenotype is discussed.

Indexed as

novel mutationoverlap syndromeTrichothiodystrophyxeroderma pigmentosumXPD-gene

Identifiers

PMID25002996
PMCPMC3916142
OpenAlexW1973141926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.